Hematologic Neoplasms
111
19
23
56
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Published Results
19 trials with published results (17%)
Research Maturity
56 completed trials (50% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
7.2%
8 terminated out of 111 trials
87.5%
+0.9% vs benchmark
11%
12 trials in Phase 3/4
34%
19 of 56 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 56 completed trials
Clinical Trials (111)
Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers
Effects of Synbiotic Supplementation on Gastrointestinal Symptoms, Appetite, and Nutritional Recovery in Patients After Autologous Bone Marrow Transplant
Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers
Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members
A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
Influenza Vaccination Strategy for Patients With Hematologic Malignancy
Musculoskeletal Ultrasound in Patients With Hematologic Malignancies
Comparison of Hemanext ONE® System and Conventional Red Blood Cell Transfusion
A Phase 1/2 Study of KK2430 in Participants With Hematologic Neoplasms
Fludarabine and Total Body Irradiation 800 Centigray (cGy) or 1125 cGy For Allogeneic Stem Cell Transplant Using Graft Versus Host Disease Prophylaxis With Post-Transplant Cyclophosphamide and Tacrolimus, Without Mycophenolate Mofetil
Ceftazidime-Avibactam PK/PD and Resistance in Hematology Patients
Anti-CD25 Monoclonal Antibody for Prevention of Acute GVHD After Haploidentical HSCT
Take5Care+: A Self-management Educational Intervention
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
Cognitive Training Intervention and Attitudes Towards Genetics
LLM-Generated Plain-Language Patient Synopses to Improve Comprehension in Hematology and Oncology (oncOPAL)
Mind-body Medicine for Patients With Malignant Hematological Diseases
UWCCC Molecular Tumor Board Registry